Stemulate human platelet lysate is the right choice for expanding human cells. Available in 100 ml and 500 ml sizes.

Hapag-Lloyd vessels are specially equipped for the transport of various goods, e.g. cargo with extraordinary / oversized dimensions, reefer cargo and dangerous goods that have to be stowed and transported according to IMO regulations. Below you will find all Hapag-Lloyd ship classes, sorted by capacity.

Human Platelet Lysate is a growth factor-rich cell culture supplement derived from healthy donor human platelets for the expansion of cells in vitro.

2005年研究發現使用人類血小板裂解濃縮液 (human Platelet Lysate, hPL)可以用來培養hMSC，對人體細胞治療臨床應用來說，HPL提供了一個新的選擇，利用HPL可以建立一個Xeno-free的細胞培養環境，在以細胞治療為目的細胞培養應用上相對更安全。

Human Platelet Lysate (hPL) products are growth factor-rich cell culture supplements for the in vitro expansion of both primary cells and stem cells, including mesenchymal stem/stromal cells (MSCs), endothelial cells (ECs), T cells, and more.

2019年7月1日 · Human platelet lysate (hPL) represents a powerful alternative to fetal bovine serum (FBS) for human mesenchymal stromal cell (hMSC) expansion. However, the large variability in hPL sources and production protocols gives rise to discrepancies in product quality, characterization and poor batch-to-batch standardization.

2020年10月22日 · HPL supplement significantly enhanced ASC proliferation without obvious change in the expression pattern of cell surface markers. We found that culturing ASCs with HPL rendered thicker cell sheets with significantly more ECM …

Herein, we compare the effects of FBS and HPL supplementation for a scalable, microcarrier-based dynamic expansion of human periosteum-derived cells (hPDCs) while assessing their bone forming capacity by subcutaneous implantation in small animal model.

2022年3月1日 · Human platelet lysate (hPL) promotes MSCs proliferation in a dose-dependent manner, whilst inhibits cell adhesion and cell spreading. RNA sequencing reveals widespread transcriptome differences between hPL-MSCs and FBS-MSCs.

We found a significant downregulation of HIF1A (hypoxia-inducible factor 1 alpha) and altered mitochondrial features in hPL-MSCs, indicating a metabolism switch of the hPL-treated cells from glycolysis towards mitochondrial oxidative phosphorylation (OxPhos).